Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enwave Corp V.ENW

Alternate Symbol(s):  NWVCF

EnWave Corporation is an applied dehydration technology company. The Company’s principal business is the licensing of its intellectual property through royalty-bearing agreements and the design, construction, marketing, and sales of vacuum-microwave dehydration machinery for the food, cannabis and biomaterial industries. It has entered into 54 royalty-bearing commercial licenses with and sold REV equipment to a diverse portfolio of companies operating in over 23 different countries on five continents. It also operates REVworx, a toll processing facility located in Delta, British Columbia that offers vacuum-microwave contract manufacturing services. The REVworx facility houses both a batch 10 kilowatt (kW) and 60 kW continuous vacuum-microwave line to accelerate the commercialization of products made with the Company’s patented technology. The Company has two primary commercial scale technologies, nutraREV, a drum-based system, and quantaREV, a tray-based system.


TSXV:ENW - Post by User

Bullboard Posts
Comment by risetothetopon Aug 24, 2018 11:01am
85 Views
Post# 28511963

RE:RE:RE:somethings up today

RE:RE:RE:somethings up todayNo doubt that the Sutro write off would cause some investors to become disheartened.  However, I have confirmed that the Merck machine has passed factory acceptance trials and will be sent to Merck's facilities in Pennsylvania in September.  It also looks like GEA was supposed to have been in this week to propose the next step for that collaboration.  Hopefully amplifying information will be included in the MD&A/news release.  
Bullboard Posts